Eos Energy stock falls after Fuzzy Panda issues short report
Intuitive Surgical (NASDAQ:ISRG), the $195.6 billion medical robotics giant trading at $550.58, saw CEO David J. Rosa sell 24,500 shares of the company’s common stock on October 24, 2025, at a weighted average price of $547.5502, for a total value of $13.4 million. The shares were sold in multiple transactions, with prices ranging from $542.16 to $550.21. According to InvestingPro analysis, the stock currently trades at a high P/E ratio of 72.7x, reflecting strong market confidence in the company’s growth prospects.
On the same day, Rosa also exercised options to acquire 27,000 shares of Intuitive Surgical common stock at a price of $79.6378, for a total value of $2,150,220. The transactions were executed under a pre-arranged trading plan that complies with SEC Rule 10b5-1, set to expire on June 11, 2026. InvestingPro data shows the company maintains excellent financial health with a "GREAT" overall score, supported by strong profitability metrics and robust cash flows.
Following the sale, Rosa directly owns 234,256 shares of Intuitive Surgical. For comprehensive insider trading analysis and additional financial metrics, access the detailed Pro Research Report available on InvestingPro, covering over 1,400 top US stocks.
In other recent news, Intuitive Surgical has reported impressive third-quarter results, with revenue reaching $2.505 billion, marking a 22.9% increase year-over-year. The company’s adjusted earnings per share were $2.40, surpassing estimates from BTIG, which anticipated $2.362 billion in revenue and $1.85 in adjusted EPS. Following these strong results, UBS raised its price target for Intuitive Surgical to $600, maintaining a Neutral rating, while Truist Securities increased its target to $620, keeping a Buy rating. Piper Sandler also raised its price target to $610, citing robust performance in both the top and bottom lines. Similarly, Leerink Partners set a new price target of $600, noting that worldwide sales exceeded consensus by 4% and da Vinci procedure growth reached 19% year-over-year. BTIG raised its target to $589, reflecting confidence in the company’s continued growth. These developments highlight the company’s strong financial performance and positive reception from analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.